Core Insights - Microbot Medical Inc. has achieved a significant milestone with Tampa General Hospital becoming the first health system in Florida to adopt the LIBERTY Endovascular Robotic System, indicating early post-clearance momentum for advanced robotic solutions in peripheral endovascular procedures [1][2] - The U.S. market for peripheral endovascular procedures is substantial, encompassing approximately 2.5 million procedures annually, presenting a significant clinical and commercial opportunity for the company [1] Company Developments - LIBERTY is the only FDA cleared, single-use, remotely operated robotic system designed for peripheral endovascular procedures, focusing on precise vascular navigation while reducing radiation exposure and physical strain [3][4] - The limited market release of the LIBERTY system commenced in late 2025, with plans for a full market release at the Society of Interventional Radiology (SIR) conference in April 2026 [3][4] - Microbot Medical is committed to innovation and has a strong intellectual property portfolio, positioning itself to transform endovascular procedures through advanced robotic technology [4] Market Positioning - Tampa General Hospital is recognized for its strong culture of innovation and clinical leadership, making it an ideal partner for the adoption of LIBERTY, which is expected to enhance care delivery and address concerns around radiation safety and ergonomic strain for physicians [2] - The company is actively engaging with additional hospitals during the limited market release and is planning to scale its commercial footprint ahead of the full market release [2]